DUBLIN--(BUSINESS WIRE)--The "Global Hepatitis C Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025" report has been added to ResearchAndMarkets.com's offering.
The global hepatitis C treatment market was valued at US$ 25.02 Bn in 2016, and is expected to reach US$ 65.48 Bn by 2025, expanding at a CAGR of 11.3% from 2017 to 2025.
For the purpose of the study hepatitis C treatment market is classified on the basis of drug type such as interferons, ribavirin and direct acting antivirals (DAA). Interferons and ribavirin are generally given in combination to increase effectiveness of ribavirin against hepatitis C.
It is estimated that DAA class will show highest market growth during forecast period due to safety and effectiveness over previous treatment approach. Newly approved medications such as zepatier (elbasvir /grazoprevir), Epclusa (sofosbuvir /velpatasvir), Mavyret (glecaprevir and pibrentasvir) and Vosevi (sofosbuvir, velpatasvir and voxilaprevir) are expected to show significant market growth during forecast period.
It is studied that currently, North America is dominating the global hepatitis C treatment market due to higher investment in drug development, large number of affected population, higher cost of medication, higher treatment awareness and upsurge in funding by the government agencies in healthcare system are major factors that driving the hepatitis C treatment market growth.
On the other hand, due to increasing healthcare awareness and developing economic condition Asia Pacific would show significant hepatitis C treatment market growth.
Key Topics Covered:
Chapter 1 Preface
Chapter 2 Executive Summary
Chapter 3 Hepatitis C Treatment Market Analysis
Chapter 4 Global Hepatitis C Treatment Market, by Drug Type
Chapter 5 Global Hepatitis C Treatment Market, by Geography
Chapter 6 Company Profiles
- AbbieVie Inc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche AG
- Gilead Sciences Inc.
- GlaxoSmith Kline Plc.
- Janssen Pharmaceuticals Inc.
- Merck & Co. Inc.
- Schering AG
- Vertex Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/research/rxdjs5/global_hepatitis?w=4